Literature DB >> 25615515

Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report.

Devipriya Rathnasabapathi, Liene Elsone, Anita Krishnan, Carolyn Young, Andrew Larner, Anu Jacob.   

Abstract

CONTEXT: Progressive myelopathy can be a manifestation of a variety of disorders including progressive multiple sclerosis. However it is extremely uncommon for a single lesion to cause a progressive myelopathy in MS. Such a myelopathy, i.e. a progressive neurological deficit from a solitary demyelinating lesion, not fulfilling the International diagnostic criteria for MS or Neuromyelitis Optica was first reported in 2012 and termed 'solitary sclerosis'.
METHOD: We report 3 further cases of progressive myelopathy fulfilling the diagnostic criteria for solitary sclerosis.
FINDINGS: Two patients had a single demyelinating lesion in the cervical cord and the third patient had it in the brain stem. All patients had serial MRI scans showing no dissemination or progression of lesions. Extensive diagnostic tests including aquaporin 4 antibodies were negative in all. At last follow-up at a median of 3.8 years, all patients continued to clinically progress despite immunosuppressive treatment. CONCLUSION/CLINICAL RELEVANCE: Solitary demyelinating lesions can cause a progressive myelopathy without clinical or radiological evidence of dissemination. Importantly, clinicians, both surgical and medical should be aware of such a diagnosis, to avoid invasive and often harmful tests particularly biopsies.

Entities:  

Keywords:  Multiple sclerosis; Myelitis; Neuromyelitis optica; Progressive; Solitary sclerosis; Spinal cord tumour

Mesh:

Year:  2015        PMID: 25615515      PMCID: PMC4612213          DOI: 10.1179/2045772314Y.0000000283

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  10 in total

Review 1.  Diagnosis and treatment of multiple sclerosis.

Authors:  T J Murray
Journal:  BMJ       Date:  2006-03-04

2.  Multiple sclerosis, solitary sclerosis or something else?

Authors:  Simona Lattanzi; Francesco Logullo; Paolo Di Bella; Mauro Silvestrini; Leandro Provinciali
Journal:  Mult Scler       Date:  2014-05-22       Impact factor: 6.312

3.  Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.

Authors:  Romain Marignier; Raphaël Bernard-Valnet; Pascale Giraudon; Nicolas Collongues; Caroline Papeix; Hélène Zéphir; Gaëlle Cavillon; Véronique Rogemond; Romain Casey; Bernard Frangoulis; Jérôme De Sèze; Sandra Vukusic; Jérôme Honnorat; Christian Confavreux
Journal:  Neurology       Date:  2013-05-08       Impact factor: 9.910

4.  Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. A new entity?

Authors:  Xavier Ayrignac; Clarisse Carra-Dalliere; Pascale Homeyer; Pierre Labauge
Journal:  Acta Neurol Belg       Date:  2013-01-29       Impact factor: 2.396

5.  Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet's disease responding to infliximab.

Authors:  Ian Coulter; Saif Huda; Atik Baborie; Anu Jacob
Journal:  J Spinal Cord Med       Date:  2012-02-08       Impact factor: 1.985

6.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

7.  Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion.

Authors:  William F Schmalstieg; B Mark Keegan; Brian G Weinshenker
Journal:  Neurology       Date:  2012-02-08       Impact factor: 9.910

Review 8.  An approach to the diagnosis of acute transverse myelitis.

Authors:  Anu Jacob; Brian G Weinshenker
Journal:  Semin Neurol       Date:  2008-02       Impact factor: 3.420

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

  10 in total
  4 in total

1.  Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion.

Authors:  B Mark Keegan; Timothy J Kaufmann; Brian G Weinshenker; Orhun H Kantarci; William F Schmalstieg; M Mateo Paz Soldan; Eoin P Flanagan
Journal:  Neurology       Date:  2016-09-16       Impact factor: 9.910

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

3.  Progressive motor neuron syndromes with single CNS lesions and CSF oligoclonal bands: never forget solitary sclerosis!

Authors:  Eleonora Giacopuzzi Grigoli; Claudia Cinnante; Pietro Emiliano Doneddu; Narghes Calcagno; Sveva Lenti; Andrea Ciammola; Luca Maderna; Nicola Ticozzi; Massimo Castellani; Sandro Beretta; Marco Rovaris; Vincenzo Silani; Federico Verde
Journal:  Neurol Sci       Date:  2022-09-19       Impact factor: 3.830

4.  Advanced imaging findings in progressive solitary sclerosis: a single lesion or a global disease?

Authors:  Lisa Eunyoung Lee; Jillian K Chan; Emilie Nevill; Adam Soares; Irene M Vavasour; Erin L MacMillan; Hideki Garren; David Clayton; B Mark Keegan; Roger Tam; Anthony L Traboulsee; Shannon H Kolind; Robert L Carruthers
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.